The price of Amneal Pharmaceuticals Inc (NASDAQ: AMRX) closed at $6.00 in the last session, down -1.96% from day before closing price of $6.12. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 1377213 shares were traded.
Ratios:
We take a closer look at AMRX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.68 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.58. For the most recent quarter (mrq), Quick Ratio is recorded 0.94 and its Current Ratio is at 1.63. In the meantime, Its Debt-to-Equity ratio is 139.06 whereas as Long-Term Debt/Eq ratio is at 127.55.
On March 08, 2021, Goldman Upgraded its rating to Buy which previously was Sell and also upped its target price recommendation from $4 to $6.50.
Guggenheim Upgraded its Neutral to Buy on December 14, 2020, while the target price for the stock was maintained at $5.50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 11 ’23 when BOYER ANDREW S sold 29,302 shares for $4.13 per share. The transaction valued at 120,921 led to the insider holds 244,739 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMRX now has a Market Capitalization of 1.85B and an Enterprise Value of 4.51B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.77 while its Price-to-Book (P/B) ratio in mrq is 92.99. Its current Enterprise Value per Revenue stands at 1.88 whereas that against EBITDA is 11.28.
Stock Price History:
Over the past 52 weeks, AMRX has reached a high of $6.46, while it has fallen to a 52-week low of $1.31. The 50-Day Moving Average of the stock is 5.70, while the 200-Day Moving Average is calculated to be 4.58.
Shares Statistics:
According to the various share statistics, AMRX traded on average about 1.51M shares per day over the past 3-months and 1.64M shares per day over the past 10 days. A total of 306.56M shares are outstanding, with a floating share count of 110.43M. Insiders hold about 64.21% of the company’s shares, while institutions hold 24.62% stake in the company. Shares short for AMRX as of Mar 15, 2024 were 2.07M with a Short Ratio of 1.37, compared to 2.1M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.67% and a Short% of Float of 0.81%.
Earnings Estimates
The company has 5 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.09 for the current quarter, with a high estimate of $0.11 and a low estimate of $0.08, while EPS last year was $0.12. The consensus estimate for the next quarter is $0.14, with high estimates of $0.15 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.63 and $0.53 for the fiscal current year, implying an average EPS of $0.58. EPS for the following year is $0.66, with 5 analysts recommending between $0.73 and $0.54.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $618.12M. It ranges from a high estimate of $631.33M to a low estimate of $606.75M. As of the current estimate, Amneal Pharmaceuticals Inc’s year-ago sales were $557.54M, an estimated increase of 10.90% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $650.37M, an increase of 8.60% less than the figure of $10.90% in the same quarter last year. There is a high estimate of $655M for the next quarter, whereas the lowest estimate is $642M.
A total of 5 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $2.63B, while the lowest revenue estimate was $2.59B, resulting in an average revenue estimate of $2.61B. In the same quarter a year ago, actual revenue was $2.39B, up 9.00% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $2.71B in the next fiscal year. The high estimate is $2.75B and the low estimate is $2.62B. The average revenue growth estimate for next year is up 3.80% from the average revenue estimate for this year.
